MiR-1912 might overcome these resistance mechanisms by p53 independent mode of action and might open a novel therapeutic option in regard to potential targeted treatment of frequent recurrent platinum-resistant ovarian cancer [58]. This evidence concerns the gene TP53 and ovarian carcinoma.